Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
Open Access
- 21 April 2021
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 16 (1) , 1-9
Abstract
Background: The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. In this study, we aimed to verify the dose-survival relationship to optimize dose selection for treatment of HCC. Methods: This multicenter retrospective study included 602 patients with HCC, treated with SBRT between January 2011 and March 2017. The SBRT dosage was classified into high dose, moderate dose, and low dose levels: SaRT (BED10 ≥ 100 Gy), SbRT (EQD2 > 74 Gy to BED10 < 100 Gy), and ScRT (EQD2 < 74 Gy). Overall survival (OS), progression-free survival (PFS), local control (LC), and intrahepatic control (IC) were evaluated in univariable and multivariable analyses. Results: The median tumor size was 5.6 cm (interquartile range [IQR] 1.1–21.0 cm). The median follow-up time was 50.0 months (IQR 6–100 months). High radiotherapy dose correlated with better outcomes. After classifying into the SaRT, SbRT, and ScRT groups, three notably different curves were obtained for long-term post-SBRT survival and intrahepatic control. On multivariate analysis, higher radiation dose was associated with improved OS, PFS, and intrahepatic control. Conclusions: If tolerated by normal tissue, we recommend SaRT (BED10 ≥ 100 Gy) as a first-line ablative dose or SbRT (EQD2 ≥ 74 Gy) as a second-line radical dose. Otherwise, ScRT (EQD2 < 74 Gy) is recommended as palliative irradiation.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81903257, 81960534)
- Natural Science Foundation of Guangxi Province (2020JJA140141)
- China International Medical Foundation-Tumor Precise Radiotherapy Spark Program (2019-N-11-01)
- National Major Science and Technology Projects of China (2017ZX10203207)
- High-level innovation team and outstanding scholar program in Guangxi Colleges and Universities
- Guangxi Medical University Training Program for Distinguished Young Scholars
- Guangxi BaGui Scholars’ Special Fund.
This publication has 30 references indexed in Scilit:
- Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinomaRadiotherapy and Oncology, 2015
- The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)Journal of Cancer Research and Clinical Oncology, 2015
- Increasing Radiation Therapy Dose Is Associated With Improved Survival in Patients Undergoing Stereotactic Body Radiation Therapy for Stage I Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Dose–response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidanceRadiotherapy and Oncology, 2014
- High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinomaRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and ToxicityPLOS ONE, 2013
- Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patientsActa Oncologica, 2013
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional StudyJournal of Thoracic Oncology, 2007